MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival - Wikidata - wikimedia - TriplyDB

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

http://www.wikidata.org/entity/Q28282398

about

Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation The MET axis as a therapeutic target.Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Biomarker development in MET-targeted therapy MET inhibitors in combination with other therapies in non-small cell lung cancer Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Improving biophysical properties of a bispecific antibody scaffold to aid developability Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Four individually druggable MET hotspots mediate HGF-driven tumor progression.The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer Pancreatic cancer: molecular pathogenesis and new therapeutic targets.Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Antibody therapeutics in cancer.The evolving genomic classification of lung cancer.Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.Targeting tumor cell motility to prevent metastasis.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.

P2860

Q21132280-A0ED7BDB-CAAD-4530-9CF3-68889E2D0121 Q24606703-0FFD549B-95B5-4C83-A375-CB39D42C661E Q24609682-E528C2BB-81A7-402C-9B93-6E9F7EA37690 Q26741814-67A5D4AD-36DD-43C7-A5AE-73A41DEED31A Q26751332-0F8ADBA8-1487-4FB3-805B-74B26A5DD606 Q26823203-3097BAF0-0603-41C8-8CA8-726FF04D27E3 Q26829104-404A9916-558F-49E1-A74F-A3F1CEA5CA35 Q27334957-B4949781-AB51-432F-89FA-217958340330 Q27679191-5556C63F-3E3A-4790-8261-370081A8A126 Q27679445-943BB8B9-68A3-40E4-9A88-25BCD7B8FF07 Q27688974-19553389-4A82-4CEA-9BC3-011A047AB18E Q28077999-5E0C086A-8670-472B-989D-F7D428E98053 Q28394310-9BD77786-5E0A-49A1-A8AC-946F906B13DC Q28478591-15C9993B-6680-4804-BB66-FBD81F98E1BB Q30494514-7497138D-822E-44ED-9D0E-3F26C68085DD Q30581656-41C23932-A9A2-4F5B-BA22-BD7445E15030 Q33563635-567C21E1-1F7E-41F2-AC8B-70278CF882F1 Q33588267-66A8BCDE-B88E-497B-8243-14730F58F48E Q33652455-EEDBC196-0FA7-4ACF-929D-6F637D5B69D4 Q33654173-A7965A68-D831-407B-AE30-C9BFB17A2928 Q33681420-93D5D3EC-7989-494A-9DDC-E1F572D7BD57 Q33769429-DD19D9D5-0D7C-4BBC-A574-16E7BC9E0853 Q33769437-680F100D-8F91-4B02-8BD7-AC3DB2AB6EB3 Q33886974-872DDE1D-D75E-43AE-B0F7-7841807B2E33 Q33899954-54DDB4F8-CC3F-4A41-B40D-E1BAD6A59173 Q33911461-65D8AE1F-CF01-4F01-BA68-0377ECCCB2BC Q34119201-CDDBDC98-2C93-445A-9748-2F6C27FA3866 Q34133016-F924AFD7-16FC-4191-9D22-EC2210495746 Q34236834-5625C916-FCB4-4F66-85BF-8031A2643A0A Q34370627-CB9F0A79-40DA-4513-844E-01354636963D Q34852043-354A28FC-8443-4A1B-80A2-5782217284C3 Q35010777-9F75B7D0-0848-4A11-B40A-F996B1F6A146 Q35051790-90BC31D0-1D78-41D0-A092-B895EBC3B39D Q35095152-E7313CED-FE6B-4B8D-8E84-8EA4D369DB10 Q35102025-E9D34A26-5E39-4CD3-AB50-05560A18357E Q35116206-2B0C8E2A-DF00-4F14-8FF6-9B7FA06ED03A Q35136424-DBDE177A-3688-49B0-A0CB-5444D6706EE8 Q35146597-1273547E-4266-4089-8DD6-D6BD434DDEAA Q35146937-A1E90EF0-A749-490F-B1A4-BF9C1903DAF6 Q35159738-63E08DE3-ED0B-4FA4-B418-6850AE75918A

P2860

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

http://www.wikidata.org/entity/Q28282398

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@ast

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@en

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@nl

type

label

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@ast

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@en

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@nl

prefLabel

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@ast

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@en

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@nl

P1433

Q28282398-432148CA-7C22-4FAA-B2FF-D06EA15EDE44

P1476

Q28282398-94E8023B-1129-4781-B400-3E1741666796

P2093

Q28282398-24087A8C-DD32-4CC2-A67E-69CB09216A2C

Q28282398-2923B44C-4BB9-4E3B-9F0D-F924B021CF13

Q28282398-490E0C7D-AB9A-485E-84F9-10A0CEFFDC45

Q28282398-4C572902-07EB-40BF-841F-422840D07C5F

Q28282398-5153DE70-F511-404F-AB77-B4B63CC0CC38

Q28282398-75230D61-49FA-4A10-8D1B-A7728D4979D8

Q28282398-930655CF-FF97-4803-A662-CA4FFA8F651F

Q28282398-9BBC3A8F-1225-4DA1-B17A-CA27C84825E4

Q28282398-A3B49E2E-1F5F-4D36-ABAF-B013ED4E10CD

Q28282398-AB4139D1-D4BD-4B11-BA86-EF0BB657F801

P304

Q28282398-8F42AF62-3616-4B68-BAB2-F9A02DD19F7A

P31

Q28282398-47D46378-1D65-4316-9CAB-0AA428967D1A

P3181

Q28282398-DD50B9B1-CA8C-457D-BB5A-A4ABDBC5A999

P356

Q28282398-F95749FD-522F-41E7-A366-4EAE4D7FC4F4

P407

Q28282398-25589CB5-020A-47DD-9110-784535C93CA7

P433

Q28282398-F4022F09-E851-4FFA-AE5B-8361671E2E4C

P478

Q28282398-F4A373AA-EBAD-4617-9140-F3E5CECC601E

P50

Q28282398-EFB7B1B0-F253-41C9-A790-F66685DFD76B

P577

Q28282398-CE15CDB6-4CEE-4483-9EAF-AF23CF42CAE7

P698

Q28282398-B8F23103-5E3C-468F-AD6F-9FEA86B4046A

P921

Q28282398-19FFA88A-BB13-4D92-9F74-35C25AA7D224

P3181

P356

0008-5472.CAN-07-5960

P1433

Cancer Research

P1476

MetMAb, the one-armed 5D5 anti ...... r growth and improves survival

@en

P2093

Elaine Mai

http://www.w3.org/2001/XMLSchema#string

Gail Colbern

http://www.w3.org/2001/XMLSchema#string

Hani Bou-Reslan

http://www.w3.org/2001/XMLSchema#string

Hongkui Jin

http://www.w3.org/2001/XMLSchema#string

Ian Kasman

http://www.w3.org/2001/XMLSchema#string

Jed Ross

http://www.w3.org/2001/XMLSchema#string

Jiping Zha

http://www.w3.org/2001/XMLSchema#string

Judy Young

http://www.w3.org/2001/XMLSchema#string

Mally Romero

http://www.w3.org/2001/XMLSchema#string

Ralph Schwall

http://www.w3.org/2001/XMLSchema#string

P304

4360-4368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3316489

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-5960

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18519697

http://www.w3.org/2001/XMLSchema#string

P921